Loading…
news
Hosted by Jeff Martin · news · EN · 35 episodes
Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
31%
Guest openness
Selective
Sign up to generate a grounded pitch for The Biotech Voyager.
Signup to Generate a PitchThe Biotech Voyager is a news podcast hosted by Jeff Martin, with 35 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
Jeff Martin hosts The Biotech Voyager, a news show with 35 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
The Biotech Voyager
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they're big news.
The Biotech Voyager
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.
The Biotech Voyager
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.
The Biotech Voyager
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Dan Tardiff, Chief Scientific Officer of CAMP4 Therapeutics, joins the show to explain how his company is using antisense oligonucleotides to upregulate gene expression by targeting regulatory RNAs, why haploinsufficient disorders represent the ideal therapeutic window for their platform, and why a modest twofold increase in transcription could transform treatment for rare neurodevelopmental diseases. CAMP4 has developed a novel approach to gene upregulation that targets non-coding regulatory RNAs transcribed from promoters and enhancers rather than the genes themselves. Dan walks through the biology of these regulatory elements, explaining how nearly universal transcription from promoters and enhancers creates a kinetic trap for transcription factors that can be modulated with antisense oligonucleotides. The platform uses genome-wide mapping techniques including chromatin accessibility, histone modifications, and Hi-C sequencing to identify regulatory regions, then confirms RNA expression through long-read sequencing before screening for therapeutic oligonucleotides. The conversation explores why ASOs offer advantages over small molecules and gene therapy for certain indications, how CAMP4's lead program in SYNGAP1-related disorder compares to Stoke Therapeutics' splice-switching approach in Dravet syndrome, the technical challenges of intrathecal delivery versus emerging blood-brain barrier shuttle technologies, and why the company expects to initiate Phase 1/2 clinical trials by the end of the year following regulatory approval in Australia and Argentina. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #CAMP4therapeutics #ASO #genetherapy #CNS #raredisease
Recent guests on The Biotech Voyager. Study who booked and why before you pitch.
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
